Stromal cell

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

Retrieved on: 
木曜日, 5月 23, 2024
Cole, Patient, Business administration, Employment, University, Abbott Laboratories, Iowa State University, Hospira, Marketing, Compensated emancipation, Prostate, Research, Growth, Breast cancer, Kidney, Stromal cell, Laboratory, GIST, St. Olaf College, Pharmaceutical industry

and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.

Key Points: 
  • and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.
  • Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches.
  • At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations.
  • “Cole’s broad commercial knowledge and leadership experience will be invaluable in helping Cogent expand from a research and development company to a fully-integrated commercial organization.”
    “I have been impressed with Cogent’s rapid progress developing bezuclastinib in multiple patient populations,” said Mr. Pinnow.

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Sunitinib, Patient, Progression-free survival, Dana–Farber Cancer Institute, SARC, Clinical trial, Safety, PEAK, Conference, Cogent, Poster, Sarcoma, Harvard Medical School, ASCO, Stromal cell, Associate, Society, APEX, GIST, KIT, Annual general meeting, Pharmaceutical industry

The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1.

Key Points: 
  • The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1.
  • “Coupled with the impressive clinical activity demonstrated by the combination, the addition of bezuclastinib to sunitinib continues to be generally well-tolerated with an encouraging safety profile.
  • “Today’s updated lead-in data from the bezuclastinib combination are very promising, and I remain excited about the ongoing PEAK trial.
  • Enrollment continues in the Phase 3 registration-enabling PEAK study, which will include approximately 388 second-line, post imatinib GIST patients.

Cogent Biosciences Reports First Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 7, 2024
AAAAI, American Academy, Brain, Safety, Stromal cell, Mouse, PEAK, Cash, Research, HER2, GIST, ASCO, Patient, Society, AACR, APEX, Edema, G&A, Growth, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2024.
  • Cogent remains on track to complete enrollment in PEAK by the end of 2024 and report top-line results by the end of 2025.
  • G&A expenses include non-cash stock compensation expense of $5.0 million for the first quarter of 2024 as compared to $2.9 million for the first quarter of 2023.
  • Net Loss: Net loss was $58.3 million for the first quarter of 2024 compared to a net loss of $38.6 million for the first quarter of 2023.

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

Retrieved on: 
水曜日, 5月 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Pfizer, Investment, NMPA, Pancreatic cancer, Schizophrenia, ASCO, HKT, Ovarian cancer, AstraZeneca, ELCC, Lung cancer, METIS, Food, CER, Genmab, Roche, GIST, CABP, Psoriasis, BLA, Bristol Myers Squibb, NSCLC, Psychosis, HKEX, NRDL, Safety, SCLC, Research and development, ABSSSI, Marketing, BMS, Clinical trial, Bronchopneumonia, GMG, TED, KarXT, Nivolumab, NDA, Stromal cell, MAA, Carcinoma, Administration, ADS, Patient, Society, Annual general meeting, Sanofi, Growth, Pharmaceutical industry

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.
  • “Our first quarter results demonstrate strong commercial execution and pipeline progress across our potential first- and best-in-class product portfolio,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab.
  • In March 2024, Zai Lab presented findings from preclinical studies highlighting the therapeutic potential of ZL-1310 at the European Lung Cancer Congress (ELCC) 2024.
  • Zai Lab to initiate a global Phase 2 study in mild-to-moderate chronic plaque psoriasis in the second quarter of 2024.

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

Retrieved on: 
火曜日, 3月 19, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Stromal cell, Amgen, American Chemical Society, University, Cornell University, Patient, Medicinal chemistry, Indiana University, Whitehead Institute, Doctor of Philosophy, Therapy, Drug development, Pharmacy, Division, Molecular biology, Takeda Oncology, Ironwood Pharmaceuticals, Pharmaceutical industry

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.

Key Points: 
  • Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.
  • Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.
  • He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018.
  • "We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution," said Jigar Patel, founder & CEO of Nimble Therapeutics.

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
月曜日, 3月 11, 2024
Therapy, Breast cancer, SAN, Pharmacology, ARIAD Pharmaceuticals, Biotechnology, Baxalta, Bone marrow, Drug development, Prostate, Acute leukemia, Acting, Stomach, Sanofi, Oxaliplatin, Astellas Pharma, Patient, Oncology, Qasr El Eyni Hospital, Stromal cell, Pancreatic cancer, IND, Head, Colorectal cancer, Cancer, Prostate cancer, Medical imaging

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Retrieved on: 
水曜日, 2月 14, 2024
Janus, Poster, AAAAI, Jefferies Group, KIT, Prospectus, APEX, Part, Sale, PEAK, Webcast, Patient, Clinical trial, United, Stromal cell, American Academy, Research, Security (finance)

WALTHAM, Mass. and BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) --  Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $225 million to the Company, before deducting placement agent fees and offering expenses.

Key Points: 
  • ET on February 23 to review the SUMMIT Part 1b data with bezuclastinib at AAAAI annual meeting
    WALTHAM, Mass.
  • J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co. acted as placement agents.
  • Cogent anticipates the gross proceeds from the private placement to be approximately $225 million, before deducting any offering-related expenses.
  • The private placement is expected to close on or about February 16, 2024, subject to customary closing conditions.

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Retrieved on: 
月曜日, 12月 11, 2023
University of Alabama, Patient, Associate, Deficit spending, Division, BID, Efficacy, Part Two, Novel, Poster, APEX, American Society of Hematology, Liver injury, PPR, KIT, Society, Stromal cell, TKI, Clinical trial, Mast cell leukemia, ASH, University, VAF, Part, Biomarker, Webcast, Safety, ASM, PEAK, GIST, MCL, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive data from Part 1 of the Company’s ongoing Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) at the 65th American Society of Hematology (ASH 2023) Annual Meeting & Exposition taking place December 9-12, 2023 in San Diego, CA.

Key Points: 
  • “Advanced systemic mastocytosis is a serious and life-threatening disease,” said Pankit Vachhani, M.D., Associate Professor of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham.
  • Patients were enrolled with the following sub-types: seven patients with aggressive systemic mastocytosis (ASM), 23 patients with systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and two patients with mast cell leukemia (MCL).
  • In addition, Cogent plans to present data from the completed SUMMIT Part 1 trial (1a and 1b) in the first quarter of 2024.
  • ET (5:00 a.m. PT) to discuss today’s APEX data and the SUMMIT data in NonAdvSM released on December 9.

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Retrieved on: 
土曜日, 12月 9, 2023
Patient, Cogent, OLE, MAS, Deficit spending, ISM, GIST, Fourth grade, Poster, Bleeding, American Society of Hematology, APEX, Disease, KIT, MD Anderson Cancer Center, Society, Stromal cell, SSM, PD, ASH, Mutation, VAF, Hyperkinesia, Part, PGIC, Webcast, Safety, University, PEAK, Dermatology, Pharmaceutical industry

Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.

Key Points: 
  • Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.
  • Patients were enrolled with the following sub-types: 18 patients with indolent systemic mastocytosis (ISM) and two patients with smoldering systemic mastocytosis (SSM).
  • In patients with completed questionnaires:
    By week 12, bezuclastinib patients showed a median best improvement of 37% on MC-QoL vs. 24% for placebo patients.
  • Data from Part 1 of the Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) will be presented in a poster session at ASH on Monday, December 11, 2023 at ASH.

Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board

Retrieved on: 
火曜日, 12月 5, 2023
Fibromatosis, Surgical oncology, Radiology, STS, AG, Treatment, ESSO, Drug development, Research, Editor-in-chief, Thermosome, CMO, Stromal cell, Bristol Myers Squibb, SSO, Therapy, ISG, BioNTech, Society, Sarcoma, Oncology, Hematology, Board certification, Senior, Pharmaceutical industry

Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.

Key Points: 
  • Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.
  • Prior to that, he was Senior Director Clinical Development Oncology at BioNTech SE and Chief Development Officer at 4SC AG.
  • Earlier in his career, Frank Hermann worked in medical affairs and clinical development at Bristol-Myers Squibb, most recently as Associate Medical Director Immuno-Oncology.
  • “We are very pleased that Frank is joining Thermosome as Chief Medical Officer,” said Dr. Pascal Schweizer, co-founder, and CEO/CFO of Thermosome.